Active ingredients: Anagrelide
Xagrid 0.5 mg hard capsules.
Hard capsule.
An opaque white hard capsule imprinted with S 063.
Each hard capsule contains 0.5 mg anagrelide (as anagrelide hydrochloride).
Excipient(s) with known effect: Each hard capsule contains lactose monohydrate (53.7 mg) and anhydrous lactose (65.8 mg).
For the full list of excipients, see section 6.1.
Anagrelide is an inhibitor of cyclic AMP phosphodiesterase III and suppress expression of transcription factors including GATA-1 and FOG-1 required for megakaryocytopoiesis, ultimately leading to reduced platelet production.
Capsule contents:
Povidone (E1201)
Lactose, anhydrous
Lactose monohydrate
Cellulose, microcrystalline (E460)
Crospovidone
Magnesium stearate
Capsule shell:
Gelatin
Titanium dioxide (E171)
Printing ink:
Shellac
Strong ammonium solution
Potassium hydroxide (E525)
Black iron oxide (E172)
High-density polyethylene (HDPE) bottles with child-resistant closures and desiccant containing 100 capsules.
Shire Pharmaceuticals Ireland Limited, Block 2 & 3 Miesian Plaza, 50 – 58 Baggot Street Lower, Dublin 2, Ireland
EU/1/04/295/001
Date of first authorisation: 16 November 2004
Date of latest renewal: 16 November 2014